Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Ultrasound Screening Criteria Proposed for Diagnosing Polycystic Kidney Disease

By HospiMedica International staff writers
Posted on 11 Nov 2008
Modification of the current screening criteria for diagnosing patients with autosomal dominant polycystic disease (ADPKD) is needed, according to researchers. More...
Their study's findings suggest that some patients with a milder form of the disease may otherwise be misdiagnosed.

ADPKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys, can lead to reduced kidney function and kidney failure. It is the most common inherited disorder of the kidney, occurring in approximately 1 in 500 births, and symptoms typically develop between the ages of 30 and 40 years.

Individuals at risk for developing ADPKD are commonly screened by imaging techniques such as ultrasound. Diagnosis can also be made with a genetic test that detects mutations in the two genes that cause the disease, called PKD1 and PKD2. However, gene-based diagnosis is expensive and detects definitive mutations in only 41% to 63% of cases. In many clinical settings, it is rarely performed.

Testing for ADPKD in individuals whose families have a history of the disease is important. Young people who know they are affected may be able to better preserve their kidney function through diet, life style modification, and blood pressure control. Testing also can be used to determine whether an at-risk individual can safely donate a kidney to a family member with the disease.

Ultrasound screening for ADPKD is based on diagnostic criteria developed to detect cases caused by mutations in the PKD1 gene. This form of the disease is more common and more severe than the form caused by mutations in the PKD2 gene. Therefore, there may be a need for different diagnostic criteria for patients with the milder, less common form of autosomal dominant polycystic disease.

To test whether this is the case, York Pei, M.D., of the University of Toronto (Toronto, ON, Canada) and his colleagues performed kidney ultrasounds and genetic tests on 577 and 371 at-risk individuals from 58 PKD1 and 39 PKD2 families, respectively. The researchers found that the ultrasound diagnostic criteria currently in use may misdiagnose individuals with mutations in the PKD2 gene. Therefore, the investigators devised new ultrasound criteria that could effectively detect the disease in individuals with mutations in either PKD1 or PKD2 gene.

The investigators determined that in families of unknown gene type, the presence of three or more kidney cysts is sufficient for establishing the diagnosis in individuals aged 15 to 39 years, two or more cysts in each kidney is sufficient for individuals aged 40 to 59 years, and four or more cysts in each kidney is required for individuals aged 60 years. Moreover, fewer than two kidney cysts in at-risk individuals aged 40 years is enough to exclude the disease. For at-risk individuals aged 30 to 39 years, the absence of any kidney cysts provides almost certainty that the disease is not present.

"For the first time we have derived a set of highly predictive criteria for ultrasound diagnosis of ADPKD that is suitable for test subjects with either gene type,” said Dr. Pei. "These unified diagnostic criteria will be useful for genetic counseling and for evaluation of at-risk subjects as living-related kidney donors for their affected relatives.”

The study was published online on October 22, 2008, in the Journal of the American Society of Nephrology (JASN).

Related Links:
University of Toronto



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.